Table 2.
Summary of the most important Stereotactic Body Radio Therapy (SBRT) series. Survival outcomes, local recurrence rate and complications are reported.
| Authors | Year | Type of study | Type of SBRT |
N. Pts |
N. Mts (%) |
Lesion size (cm) (range) |
Primary Site | Previous CT | Dose range (Gy/fxs) | BED10Gy | Median FU (months) |
Median OS (months) |
1y OS (%) |
2 OS (%) |
1y LC (%) |
2y LC (%) |
Toxicity (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scorsetti | 2015 | Phase 2 | VMAT | 42 | 1 (81 %) | 1.1–5.4 | Colon (71%); rectum (29%) |
– | 75/3 | 262.5 | 24 | 29 | – | 65 | 95 | 91 | G2 liver toxicity (25) |
| Stintzing | 2013 | Prospective series | Cyberknife | 30 | 1 (86%) | 0.7–5.3 | – | – | 24–26/1 | 81.6–93.6 | 23.3 | 34.4 | – | – | 85 | 80 | Bleeding and rising bilirubin (3) |
| van de Voorde | 2015 | Retrospective | VMAT | 17 | – | – | – | – | EQ2 62–150/3-10 | – | 21 | 25 | – | – | – | – | – |
| van der Pool | 2010 | Prospective series | LINAC | 20 | 31 (total) | 0.7–6.2 | Colon (75%); rectum (25%) |
– | 37.5–45/3 | 93.6–112.5 | 26 | 34 | 100 | 83 | 74 | G3 liver toxicity (10), G2 (90) |
|
| Vautravers-Dewas | 2011 | Retrospective | Not specified | 30 | 62 (total) | 0.7–10 | – | – | 40/4 | 80 | 14.3 | – | – | 58 | 86 | – | |
| 45/3 | 112.5 | ||||||||||||||||
| Ahmed | 2016 | Retrospective | Not specified | 22 | 2 (0–5) | 2 (0.6–6.7) |
Colorectal | 2 lines | 50–60/5 | 100–132 | 20.5 | – | 100 | 73 | 79 | 59 | – |
| Ambrosino | 2009 | Prospective series | Cyberknife | 11 | 1.8 | – | Colorectal | – | 25–60/3 | 45.83–180 | 13 | – | – | – | – | – | G1-2 liver toxicity (36.4) |
| Berber | 2013 | Retrospective | Cyberknife | 53 | 1.6 | – | Colorecta | – | 41/3 | 96.76 | 17 | – | 56 | – | 60 | – | G1 fatigue and nausea (21); Death n = 1 |
| Chang | 2011 | Retrospective cohort (pooled analysis) |
Cyberknife | 65 | 1–2 (80%) | – | Colorectal/ | – | 22–60/1-6 | 40.5–180 | 14 | – | 72 | 38 | 62 | 45 | GI-G2 & G3 acute GI toxicity (17&3) |
| Mendez Romero | 2016 | Retrospective | LINAC & Cyberknife |
40 | 1–2 (95%) | 2.5 (0.7–6.2) |
Colorectal | – | 50.25/3 | 134.42 | 25 | 43 | 94 | 81 | 93 | 90 | G1-2 liver toxicity (97.5), G3 liver toxicity (7.5) |
| 37.5/3 | 84.38 | 26 | 35 | 95 | 69 | 96 | 74 | – | |||||||||
| Doi | 2017 | Retrospective | LINAC | 24 | 1 (75%) | 3.5 (7–11.6) |
Colon (75%); rectum (25%) |
Yes (87.5%) | 45–72/8 | 71.7–115.5 | 16 | 45 | 82.3 | 67.1 | 67.2 | 35.9 | G1-2 liver toxicity (16), duodenal ulcer (4) |
| Goodman | 2016 | Retrospective | LINAC | 54 | – | – | – | – | 32–60/3–5 | 52.48–180 | 33 | 38 | 95 | 78 | 93 | 88 | Death n = 1 |
| Hoyer | 2006 | Phase 2 | LINAC | 44 | – | 3.5 | Colon (59%); rectum (41) |
Yes (52%) | 45/3 | 112.5 | 52 | 19.2 | – | 38 | – | 78 | G3 intestinal toxicity (5), liver failure (2), G1-2 nausea & diarrhea (34 & 23), G3 (3); Death n = 1 |
| Joo | 2017 | Retrospective | LINAC | 70 | 1–2 (86%) | 2.9 | – | 0–2 lines (69%) |
45–60/3-4 | 58–180 | 34.2 | – | – | 75 | – | – | G1-2 nausea (34), G1-2 liver toxicity (15) |
| Kim | 2009 | Prospective series | Cyberknife | 10 | 14 | – | Colon (60%); rectum (40%) |
>1line (100%) |
36–51/3 | 79.2–137.7 | 12 | 25 | 53.00 | 40 | 80 | 60 | G1 nausea and musculoskeletal discomfort (40) |
| Lee | 2009 | Phase 1 | Not specified | 40 | 2 (1–8) | – | – | >1 line (85%) |
27.7–60/6 | 40.44–120 | 10.8 | 15 | 63 | – | – | – | – |
| Liu | 2013 | Retrospective | Not specified | 24 | 1–4 | – | – | – | 24–60/1-5 | 81.6–132 | 18 | 25.2 | – | – | 86 | 67 | – |
| McPartlin | 2017 | Phase 1 & 2 | Not specified | 60 | 1 (1–6) | – | – | >1 line (82%) |
22.7–62.1/6 | 31.28–126.37 | 28.1 | 16 | 63 | 26 | 50 | 32 | G3 nausea (2) |
| Jackson | 2018 | Retrospective | Not specified | 92 | 2 | 2.7 (0.0–9.2) |
Colorectal (19.4%) | >1 line | 50Gy/5 | >80 | 20.2 | 24.5 | 75 | 50.2 | 96 | 88.2 | Gastronitestinal bleeding and rising bilirubin (4) |